Summary
RYBREVANT and LAZCLUZE combination shows significant overall survival benefit in EGFR-mutated NSCLC patients, exceeding one year median survival improvement over standard osimertinib treatment.
New Lung Cancer Treatment Shows Promise in Extending Survival
Johnson & Johnson recently announced positive results from a clinical trial for its lung cancer drugs, RYBREVANT and LAZCLUZE. The study, known as the MARIPOSA trial, showed that the combination of these two drugs significantly improved overall survival in patients with a specific type of lung cancer called EGFR-mutated non-small cell lung cancer (NSCLC).
The trial involved 1,074 patients and compared the effectiveness of RYBREVANT plus LAZCLUZE against the current standard treatment, osimertinib. The results showed that the combination of RYBREVANT and LAZCLUZE extended median overall survival by more than a year compared to osimertinib. This is a significant improvement, as less than 20% of patients with EGFR-positive lung cancer live beyond five years.
The study’s findings are important because they provide a new treatment option for patients with EGFR-mutated NSCLC. The combination of RYBREVANT and LAZCLUZE is a chemotherapy-free regimen, which means it does not involve the use of chemotherapy. This is a significant advantage, as chemotherapy can have severe side effects.
The MARIPOSA trial’s results are also notable because they demonstrate the first overall survival benefit over the current standard of care. This means that RYBREVANT plus LAZCLUZE is the first treatment to show a significant improvement in survival rates compared to the current standard treatment.
According to Yusri Elsayed, MD, global therapeutic area head of oncology at Johnson & Johnson Innovative Medicine, “These new findings reinforce the clinically meaningful impact this chemotherapy-free regimen can have for patients worldwide with non-small cell lung cancer and represent the first overall survival benefit over the current standard of care.”
The approval of RYBREVANT plus LAZCLUZE is a significant step forward in the treatment of lung cancer. It provides a new option for patients and offers hope for improved survival rates.
Sources:
- Johnson & Johnson Press Release (2025-01-07)
- Respiratory Therapy (2025-01-07)
- Applied Clinical Trials Online (2025-01-07)